VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis
暂无分享,去创建一个
S. Owatari | A. Utsunomiya | Takuhiro Yamaguchi | S. Fuji | Y. Inoue | Y. Moriuchi | E. Otsuka | T. Fukuda | S. Yoshida | T. Miyagi | Yasushi Sawayama
[1] G. Barber,et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. , 2018, Blood advances.
[2] S. Yamasaki,et al. Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis , 2018, Bone Marrow Transplantation.
[3] S. Owatari,et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation , 2017, Haematologica.
[4] A. Utsunomiya,et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Ueda,et al. Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study , 2015, British journal of haematology.
[6] K. Ishitsuka,et al. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. , 2014, The Lancet. Oncology.
[7] K. Tsukasaki,et al. Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience , 2014, International Journal of Hematology.
[8] S. Nomura,et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long‐term survivors of aggressive adult T‐cell leukaemia‐lymphoma (JCOG0902A) , 2014, British journal of haematology.
[9] A. Bazarbachi,et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Yamaguchi,et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Ueda,et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Tomonaga,et al. A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.
[13] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[14] A. Nagler,et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP , 2014, Bone Marrow Transplantation.